The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays
Open accessAbstract
SARS-CoV-2 enters cells using its Spike protein, which is also the main target of neutralizing antibodies. Therefore, assays to measure how antibodies and sera affect Spike-mediated viral infection are important for studying immunity. Because SARS-CoV-2 is a biosafety-level-3 virus, one way to simplify such assays is to pseudotype biosafety-level-2 viral particles with Spike. Such pseudotyping has now been described for single-cycle lentiviral, retroviral, and vesicular stomatitis virus (VSV) particles, but the reagents and protocols are not widely available. Here, we detailed how to effectively pseudotype lentiviral particles with SARS-CoV-2 Spike and infect 293T cells engineered to express the SARS-CoV-2 receptor, ACE2. We also made all the key experimental reagents available in the BEI Resources repository of ATCC and the NIH. Furthermore, we demonstrated how these pseudotyped lentiviral particles could be used to measure the neutralizing activity of human sera or plasma against SARS-CoV-2 in convenient luciferase-based assays, thereby providing a valuable complement to ELISA-based methods that measure antibody binding rather than neutralization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
A new coronavirus associated with human respiratory disease in China
Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2008-3 · Cited by 11,688 · cited 2×
“The Spike protein was from SARS-CoV-2 strain Wuhan-Hu-1 using the NCBI-annotated start site [46], with the ucleotide sequence codon optimized for expression in human cells.”
MethodCryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Self-citationDetection of SARS-CoV-2 in Different Types of Clinical Specimens
Wang, W., Xu, Y., Gao, R., Lu, R., Han, K., Wu, G., & Tan, W. (2020) · JAMA · doi:10.1001/jama.2020.3786 · Cited by 5,028
Letko, M., Marzi, A., & Munster, V. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0688-y · Cited by 3,109
Ou, X., Liu, Y., Lei, X., Li, P., Mi, D., Ren, L., Guo, L., Guo, R., Chen, T., Hu, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15562-9 · Cited by 3,097
Antibody responses to SARS-CoV-2 in patients with COVID-19
Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876
Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019
Zhao, J., Yuan, Q., Wang, H., Liu, W., Liao, X., Su, Y., Wang, X., Yuan, J., Li, T., Li, J., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa344 · Cited by 2,607
Effectiveness of convalescent plasma therapy in severe COVID-19 patients
Duan, K., Liu, B., Li, C., Zhang, H., Yu, T., Qu, J., Zhou, M., Chen, L., Meng, S., Hu, Y., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2004168117 · Cited by 1,960
Stability of SARS-CoV-2 in different environmental conditions
Chin, A. W. H., Chu, J. T. S., Perera, M. R. A., Hui, K. P. Y., Yen, H.-L., Chan, M. C. W., Peiris, M., & Poon, L. L. M. (2020) · doi:10.1101/2020.03.15.20036673 · Cited by 1,948 · cited 1×
“This duration of heat treatment has been shown to be sufficient to inactivate SARS-CoV-2 [26,57], which is also not reported to be present at high titers in the blood [58,59].”
Stability of SARS-CoV-2 in different environmental conditions
Chin, A. W. H., Chu, J. T. S., Perera, M. R. A., Hui, K. P. Y., Yen, H.-L., Chan, M. C. W., Peiris, M., & Poon, L. L. M. (2020) · The Lancet Microbe · doi:10.1016/s2666-5247(20)30003-3 · Cited by 1,946
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2349-y · Cited by 1,885
Self-citationA serological assay to detect SARS-CoV-2 seroconversion in humans
Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., Jiang, K., Arunkumar, G. A., Jurczyszak, D., Polanco, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0913-5 · Cited by 1,769 · cited 2×
“However, while there are now well-characterized and high-throughput methods (such as ELISA assays) to measure total antibody binding to SARS-CoV-2 or some of its key constituent proteins [2,6,26], quantifying neutralizing antibody activity is more difficult.”
BackgroundStructural and functional analysis of a potent sarbecovirus neutralizing antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · doi:10.1101/2020.04.07.023903 · Cited by 1,752
Self-citationHuman neutralizing antibodies elicited by SARS-CoV-2 infection
Ju, B., Zhang, Q., Ge, J., Wang, R., Sun, J., Ge, X., Yu, J., Shan, S., Zhou, B., Song, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2380-z · Cited by 1,667
Okba, N. M. A., Müller, M. A., Li, W., Wang, C., GeurtsvanKessel, C. H., Corman, V. M., Lamers, M. M., Sikkema, R. S., de Bruin, E., Chandler, F. D., et al. (2020) · Emerging Infectious Diseases · doi:10.3201/eid2607.200841 · Cited by 1,614
A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV
Yuan, M., Wu, N. C., Zhu, X., Lee, C.-C. D., So, R. T. Y., Lv, H., Mok, C. K. P., & Wilson, I. A. (2020) · Science · doi:10.1126/science.abb7269 · Cited by 1,463
Tian, X., Li, C., Huang, A., Xia, S., Lu, S., Shi, Z., Lu, L., Jiang, S., Yang, Z., Wu, Y., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1729069 · Cited by 1,252
Use of convalescent plasma therapy in SARS patients in Hong Kong
Cheng, Y., Wong, R., Soo, Y. O. Y., Wong, W. S., Lee, C. K., Ng, M. H. L., Chan, P., Wong, K. C., Leung, C. B., & Cheng, G. (2005) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1271-9 · Cited by 958
Deployment of convalescent plasma for the prevention and treatment of COVID-19
Bloch, E. M., Shoham, S., Casadevall, A., Sachais, B. S., Shaz, B., Winters, J. L., van Buskirk, C., Grossman, B. J., Joyner, M., Henderson, J. P., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138745 · Cited by 799
Wu, F., Wang, A., Liu, M., Wang, Q., Chen, J., Xia, S., Ling, Y., Zhang, Y., Xun, J., Lu, L., et al. (2020) · doi:10.1101/2020.03.30.20047365 · Cited by 754
Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2
Nie, J., Li, Q., Wu, J., Zhao, C., Hao, H., Liu, H., Zhang, L., Nie, L., Qin, H., Wang, M., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1743767 · Cited by 711
The time course of the immune response to experimental coronavirus infection of man
Callow, K. A., Parry, H. F., Sergeant, M., & Tyrrell, D. A. J. (1990) · Epidemiology and Infection · doi:10.1017/s0950268800048019 · Cited by 598
SARS-like WIV1-CoV poised for human emergence
Menachery, V. D., Yount, B. L., Sims, A. C., Debbink, K., Agnihothram, S. S., Gralinski, L. E., Graham, R. L., Scobey, T., Plante, J. A., Royal, S. R., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1517719113 · Cited by 418
Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections
Lv, H., Wu, N. C., Tsang, O. T.-Y., Yuan, M., Perera, R. A. P. M., Leung, W. S., So, R. T. Y., Chan, J. M. C., Yip, G. K., Chik, T. S. H., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107725 · Cited by 407
Subbarao, K., McAuliffe, J., Vogel, L., Fahle, G., Fischer, S., Tatti, K., Packard, M., Shieh, W.-J., Zaki, S., & Murphy, B. (2004) · Journal of Virology · doi:10.1128/jvi.78.7.3572-3577.2004 · Cited by 406
Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig
Lei, C., Qian, K., Li, T., Zhang, S., Fu, W., Ding, M., & Hu, S. (2020) · Nature Communications · doi:10.1038/s41467-020-16048-4 · Cited by 392
Soo, Y. O. Y., Cheng, Y., Wong, R., Hui, D. S., Lee, C. K., Tsang, K. K. S., Ng, M. H. L., Chan, P., Cheng, G., & Sung, J. J. Y. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2004.00956.x · Cited by 381
The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus
Karlsson Hedestam, G. B., Fouchier, R. A. M., Phogat, S., Burton, D. R., Sodroski, J., & Wyatt, R. T. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1819 · Cited by 339
Chen, X., Li, R., Pan, Z., Qian, C., Yang, Y., You, R., Zhao, J., Liu, P., Gao, L., Li, Z., et al. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0426-7 · Cited by 332
Moore, M. J., Dorfman, T., Li, W., Wong, S. K., Li, Y., Kuhn, J. H., Coderre, J., Vasilieva, N., Han, Z., Greenough, T. C., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.19.10628-10635.2004 · Cited by 243
A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus
Gunn, B. M., Yu, W.-H., Karim, M. M., Brannan, J. M., Herbert, A. S., Wec, A. Z., Halfmann, P. J., Fusco, M. L., Schendel, S. L., Gangavarapu, K., et al. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.07.009 · Cited by 218
Corti, D., Zhao, J., Pedotti, M., Simonelli, L., Agnihothram, S., Fett, C., Fernandez-Rodriguez, B., Foglierini, M., Agatic, G., Vanzetta, F., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1510199112 · Cited by 216
Antibody Responses to SARS-CoV-2 in Patients of Novel Coronavirus Disease 2019
Zhao, J., Yuan, Q., Wang, H., Liu, W., Liao, X., Su, Y., Wang, X., Yuan, J., Li, T., Li, J., et al. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3546052 · Cited by 208
Stability of SARS-CoV-2 in different environmental conditions
Dehbandi, R., & Zazouli, M. A. (2020) · The Lancet Microbe · doi:10.1016/s2666-5247(20)30093-8 · Cited by 193
McBride, C. E., Li, J., & Machamer, C. E. (2007) · Journal of Virology · doi:10.1128/jvi.02146-06 · Cited by 182
Xiong, H.-L., Wu, Y.-T., Cao, J.-L., Yang, R., Liu, Y.-X., Ma, J., Qiao, X.-Y., Yao, X.-Y., Zhang, B.-H., Zhang, Y.-L., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1815589 · Cited by 161
Longitudinally Profiling Neutralizing Antibody Response to SARS Coronavirus with Pseudotypes
Temperton, N. J., Chan, P. K. S., Simmons, G., Zambon, M. C. F. A., Tedder, R. S., Takeuchi, Y., & Weiss, R. A. (2005) · Emerging infectious diseases · doi:10.3201/eid1103.040906 · Cited by 157
Kapadia, S. U., Rose, J. K., Lamirande, E. W., Vogel, L., Subbarao, K., & Roberts, A. (2005) · Virology · doi:10.1016/j.virol.2005.06.016 · Cited by 155
Reed, S. E. (1984) · Journal of Medical Virology · doi:10.1002/jmv.1890130208 · Cited by 147 · cited 1×
“Indeed, for other coronaviruses, neutralizing antibodies are protective in mouse models of infection [16–20] and associated with at least some reduced susceptibility to re-infection or disease in humans [15,21,22].”
BackgroundAn optimized method for high-titer lentivirus preparations without ultracentrifugation
Jiang, W., Hua, R., Wei, M., Li, C., Qiu, Z., Yang, X., & Zhang, C. (2015) · Scientific Reports · doi:10.1038/srep13875 · Cited by 145
Retroviral Vectors Pseudotyped with Severe Acute Respiratory Syndrome Coronavirus S Protein
Giroglou, T., Cinatl, J. J., Rabenau, H. F., Drosten, C., Schwalbe, H., Doerr, H. W., & von Laer, D. (2004) · Journal of Virology · doi:10.1128/jvi.78.17.9007-9015.2004 · Cited by 145
Quinlan, B. D., Mou, H., Zhang, L., Guo, Y., He, W., Ojha, A., Parcells, M. S., Luo, G., Li, W., Zhong, G., et al. (2020) · doi:10.1101/2020.04.10.036418 · Cited by 140
Rockx, B., Corti, D., Donaldson, E., Sheahan, T., Stadler, K., Lanzavecchia, A., & Baric, R. (2008) · Journal of Virology · doi:10.1128/jvi.02377-07 · Cited by 134 · cited 1×
“Indeed, for other coronaviruses, neutralizing antibodies are protective in mouse models of infection [16–20] and associated with at least some reduced susceptibility to re-infection or disease in humans [15,21,22].”
BackgroundCribbs, A. P., Kennedy, A., Gregory, B., & Brennan, F. M. (2013) · BMC Biotechnology · doi:10.1186/1472-6750-13-98 · Cited by 134
Fukushi, S., Mizutani, T., Saijo, M., Matsuyama, S., Miyajima, N., Taguchi, F., Itamura, S., Kurane, I., & Morikawa, S. (2005) · Journal of General Virology · doi:10.1099/vir.0.80955-0 · Cited by 132
Callow, K. A. (1985) · Journal of Hygiene · doi:10.1017/s0022172400062410 · Cited by 119
Khan, S., Nakajima, R., Jain, A., de Assis, R. R., Jasinskas, A., Obiero, J. M., Adenaiye, O., Tai, S., Hong, F. H., Milton, D. K., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.24.006544 · Cited by 118
Optimization of the Transductional Efficiency of Lentiviral Vectors: Effect of Sera and Polycations
Denning, W. L., Das, S., Guo, S., Xu, J., Kappes, J. C., & Hel, Z. (2012) · Molecular Biotechnology · doi:10.1007/s12033-012-9528-5 · Cited by 110
Bootz, A., Karbach, A., Spindler, J., Kropff, B., Reuter, N., Sticht, H., Winkler, T., Britt, W. J., & Mach, M. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006601 · Cited by 104
Murine Leukemia Virus (MLV)-based Coronavirus Spike-pseudotyped Particle Production and Infection
Millet, J., & Whittaker, G. (2016) · BIO-PROTOCOL · doi:10.21769/bioprotoc.2035 · Cited by 91
Structural and functional analysis of a potent sarbecovirus neutralizing antibody
Pinto, D., Park, Y., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., Marco, A. D., et al. (2020) · Worldwide Protein Data Bank · doi:10.2210/pdb6ws6/pdb · Cited by 87
Self-citationPotent neutralization of 2019 novel coronavirus by recombinant ACE2-IgPreprint
Lei, C., Fu, W., Qian, K., Tian, L., Zhang, S., Ding, M., & Hu, S. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.02.01.929976 · Cited by 85
To, K. K., Zhang, J., Hung, I. F., Xu, T., Ip, W. C., Wong, R. T. Y., Ng, J. C. K., Chan, J. F., Chan, K., & Yuen, K. (2012) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00081-12 · Cited by 83
An optimised method for the production of MERS-CoV spike expressing viral pseudotypes
Grehan, K., Ferrara, F., & Temperton, N. J. (2015) · MethodsX · doi:10.1016/j.mex.2015.09.003 · Cited by 66
A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike GlycoproteinPreprint
Joyce, M. G., Sankhala, R. S., Chen, W., Choe, M., Bai, H., Hajduczki, A., Yan, L., Sterling, S. L., Peterson, C. E., Green, E. C., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.15.992883 · Cited by 45
Co, M. D. T., Terajima, M., Thomas, S. J., Jarman, R. G., Rungrojcharoenkit, K., Fernandez, S., Yoon, I., Buddhari, D., Cruz, J., & Ennis, F. A. (2014) · Viral Immunology · doi:10.1089/vim.2014.0061 · Cited by 44
Schwegmann‐Weßels, C., Glende, J., Ren, X., Qu, X., Deng, H., Enjuanes, L., & Herrler, G. (2009) · Journal of General Virology · doi:10.1099/vir.0.009704-0 · Cited by 38
Cytoplasmic tail of coronavirus spike protein has intracellular targeting signals
Sadasivan, J., Singh, M., & Sarma, J. D. (2017) · Journal of Biosciences · doi:10.1007/s12038-017-9676-7 · Cited by 37
Lester, S. N., Harcourt, J. L., Whitt, M. A., Al-Abdely, H. M., Midgley, C. M., Alkhamis, A. M., Jokhdar, H., Assiri, A. M., Tamin, A., & Thornburg, N. J. (2019) · Access Microbiology · doi:10.1099/acmi.0.000057 · Cited by 19
Cited by
Starr, T. N., Greaney, A. J., Hilton, S. K., Ellis, D., Crawford, K. H. D., Dingens, A. S., Navarro, M. J., Bowen, J. E., Tortorici, M. A., Walls, A. C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.012 · Cited by 1,956
“Finally, we validated the deep mutational scanning measurements in the context of spike-pseudotyped lentiviral particles (Figures 4H and S4J; Crawford et al., 2020).”
InfluentialSelf-citationMultiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
Garcia-Beltran, W. F., Lam, E. C., St. Denis, K., Nitido, A. D., Garcia, Z. H., Hauser, B. M., Feldman, J., Pavlovic, M. N., Gregory, D. J., Poznansky, M. C., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.013 · Cited by 1,353
Self-citationGreaney, A. J., Loes, A. N., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.02.003 · Cited by 1,178
Self-citationmRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant
Garcia-Beltran, W. F., St. Denis, K. J., Hoelzemer, A., Lam, E. C., Nitido, A. D., Sheehan, M. L., Berrios, C., Ofoman, O., Chang, C. C., Hauser, B. M., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.033 · Cited by 1,045
“neutralization assay that we and others have previously validated (Crawford et al., 2020; GarciaBeltran et al., 2021b; Ju et al., 2020; Moore et al., 2004; Pinto et al., 2020; Wang et al., 2020; Yang et al., 2020) to assess SARS-CoV-2 variant neutralization (Figure 2B).”
InfluentialSelf-citationN-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2
McCallum, M., De Marco, A., Lempp, F. A., Tortorici, M. A., Pinto, D., Walls, A. C., Beltramello, M., Chen, A., Liu, Z., Zatta, F., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.028 · Cited by 901
“For neutralization, stable 293T cells expressing ACE2 (Crawford et al., 2020) in DMEM supplemented with 10%FBS, 1%PenStrep were seeded at 40,000 cells/well into clear bottom white walled 96-well plates and cultured overnight at 37 C.”
InfluentialSelf-citation
Metadata
- Authors
- Crawford, K. H. D., Eguia, R., Dingens, A. S., Loes, A. N., Malone, K. D., Wolf, C. R., Chu, H. Y., Tortorici, M. A., Veesler, D., Murphy, M., Pettie, D., King, N. P., Balazs, A. B., & Bloom, J. D.
- Venue
- Viruses
- Publisher
- MDPI AG
- Published
- 2020-05-06
- Volume
- 12
- Issue
- 5
- Pages
- 513
- ISSN
- 1999-4915 (ISSN-L)
- OpenAlex
- W3020828664
- Cited by
- 776
- References
- 62
- FWCI
- 17.47
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.